Vera Therapeutics, Inc. (VERA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
the bull case· 4
4
funds on file reporting a position in VERA
n-portas of Jun 30 '261.06%
of State Street SPDR S&P Biotech ETF's assets largest fund weight on file
n-portJun 30 '26222
managers reporting a position in the latest quarterly filings
13fJun 30 '26+7.86%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 2
7 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized4 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
High 35.00 at 4:00 pm ET, low 33.48 at 2:30 pm ET.
Vera Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Of the 6 companies Vera Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
VERA (Vera Therapeutics, Inc.) has 4 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
221 managers report a position worth $3.4B between them, and 28 of them hold 80% of it.